Симуляция графика K-линий, фактические данные указаны на торговой странице
Ключевые данные
Открытие вчера
$1.38
Пред. закрытие
$1.64
Вчерашний диапазон
$1.37 - $1.64
Диапазон 52 нед.
$0.56 - $2.72
Объем торговли
15.085M
МС
$262.23M
P/E
--
EPS
$-0.58
Обзор компании
NASDAQ
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases associated with the human papillomavirus (HPV), cancer, and infectious diseases.
СекторHEALTHCARE
ОтрасльBIOTECHNOLOGY
Штаб-квартира660 WEST GERMANTOWN PIKE, PLYMOUTH MEETING, PA, UNITED STATES, 19462
Inovio Pharmaceuticals, Inc. (INO) is a biotechnology company focused on developing DNA-based immunotherapies and vaccines to treat and prevent infectious diseases, cancer, and other conditions. The company utilizes its proprietary DNA medicines platform to create treatments designed to activate the immune system.
Inovio Pharmaceuticals, Inc. operates in the Healthcare sector and is categorized within the Biotechnology industry. It specializes in the development of advanced immunotherapies and DNA-based solutions targeting unmet medical needs.
As a biotechnology company, Inovio Pharmaceuticals' revenue is primarily driven by collaboration agreements, research grants, and potential licensing of its DNA-based technology. Additionally, future revenue may hinge on the successful commercialization of its therapies and vaccines currently in development.
Investing in Inovio Pharmaceuticals carries risks typical of biotech companies, including dependency on clinical trial success, regulatory approvals, and funding for research and development. Additionally, competition from other biotech firms and market volatility in the healthcare sector may pose challenges.
Inovio differentiates itself with its proprietary DNA medicines platform, which focuses on developing therapies designed to trigger targeted immune responses. This innovative technology distinguishes it from competitors utilizing more traditional biopharmaceutical approaches.
No, Inovio Pharmaceuticals does not currently pay a dividend to shareholders. As a biotechnology company focused on research and development, it typically reinvests its resources into advancing its pipeline of therapeutics and vaccines.
Key opportunities for Inovio Pharmaceuticals include its potential to address unmet medical needs with its DNA-based therapies, the ability to secure strategic partnerships, and the advancement of its pipeline into later-stage clinical trials, which could lead to regulatory approvals and commercialization.
Inovio Pharmaceuticals faces competition from other biotechnology companies developing immunotherapies and treatments, such as Moderna, BioNTech, and Novavax. These firms also focus on vaccines and therapies for infectious diseases and cancers, presenting competition in both innovation and market share.
Предупреждение о рисках
1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.